Influence of ATLG dosing on posttransplant immune reconstitution in recipients of CD3/CD19–depleted stem cell grafts. FACS analysis of (A) CD3⁺ T cells, (B) CD4⁺ T cells, (C) CD8⁺ T cells, (D) CD19⁺ B cells, and (E) CD56⁺ NK cells at days +30, +90, and +365 after transplant in patients treated with 15 mg/kg, 30 mg/kg, or 60 mg/kg ATLG before HSCT. Shown are scatterplots with median cell numbers per μL of all patients without graft rejection. Statistical analysis: Kruskal-Wallis test (A-E).